drugset / Trial / NCT00890734

CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

NCT00890734 ↗

Phase 2 Completed 63 enrolled Cytos Biotechnology AG
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.

Timeline

Start
2009-04
Primary completion
2010-04
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CYT003-QbG10 Vaccine — Subcutaneous

Indications